CPRX Q1 2024 Earnings — Catalyst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

CPRXCatalyst Pharmaceuticals, Inc.

$3B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$99M+15.4% YoY

Gross Profit

$86M87.3% margin

Operating Income

$27M27.5% margin

Net Income

$23M23.6% margin

EPS (Diluted)

$0.19

QoQ Revenue Growth

-10.9%

Cash Flow

Operating Cash Flow

$32M

Free Cash Flow

$32M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$647M

Total Liabilities

$85M

Stockholders' Equity

$561M

Cash & Equivalents

$310M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$99M	$85M	+15.4%
Gross Profit	$86M	$75M	+14.0%
Operating Income	$27M	$36M	-23.8%
Net Income	$23M	$30M	-21.3%

Revenue Segments

Product Revenue Net

$98M100%

License And Other Revenue

$68,0000%